Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail, M Rehman, HS Sarwar… - International journal …, 2018 - Taylor & Francis
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …
被引用次数：120 相关文章
[PDF] scienceopen.com

[PDF][PDF] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail - International Journal of Nanomedicine, 2018 - scienceopen.com
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …

Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail, M Rehman, HS Sarwar… - International …, 2018 - pubmed.ncbi.nlm.nih.gov
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …

[引用][C] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail, M Rehman, HS Sarwar, S Naveed… - International Journal of …, 2018 - cir.nii.ac.jp
Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future
trends | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail, M Rehman, HS Sarwar, S Naveed… - International Journal of …, 2018 - go.gale.com
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …

Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.

MF Sohail, M Rehman, HS Sarwar… - International Journal …, 2018 - europepmc.org
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …
[HTML] nih.gov

[HTML][HTML] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail, M Rehman, HS Sarwar… - International Journal …, 2018 - ncbi.nlm.nih.gov
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …
[PDF] academia.edu

[PDF][PDF] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail - International Journal of Nanomedicine, 2018 - academia.edu
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …
[HTML] dovepress.com

[HTML][HTML] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail, M Rehman, HS Sarwar… - International Journal …, 2018 - dovepress.com
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …
[PDF] semanticscholar.org

[PDF][PDF] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

MF Sohail - International Journal of Nanomedicine, 2018 - pdfs.semanticscholar.org
The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability,
gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus …